Assuming therapy is required, the following results were found.

  • Researchers find possible causes for lacking of effective therapy for multiple sclerosis

    disability becoming progressively worse. This type cannot be sufficiently treated at yet. Possible causes why an effective therapy for progressive MS is still lacking have been compiled by an international research team in a review article in the...

    https://mschristian.org/index.php/blog/researchers-find-possible-causes-for-lacking-of-effective-therapy-for-multiple-sclerosis
  • #ECTRIMS2019 - Mayzent's Benefits for MS Patients a 'Key Question,' Says EXPAND's Principal Investigator - Multiple Sclerosis News Today

    The most recent data continue to support Mayzent‘s (siponimod) benefits and provide more insights on how this therapy can make a difference for those with relapsing forms of multiple sclerosis (MS) — in particular, data showing the therapy lowers the...

    https://mschristian.org/index.php/blog/ectrims2019-mayzent-s-benefits-for-ms-patients-a-key-question-says-expand-s-principal-investigator-multiple-sclerosis-news-today
  • Diving into aquatic therapy | Local | columbustelegram.com - Columbus Telegram

    into aquatic therapy | Local | columbustelegram.com Columbus Telegram Aquatic therapy, also known as hydrotherapy or pool therapy, uses the physical properties of water to help participants exercise with the goal of helping them... Original link Diving...

    https://mschristian.org/index.php/blog/diving-into-aquatic-therapy-local-columbustelegram-com-columbus-telegram
  • Treating pediatric MS

    In 2018 the U.S. Food and Drug Administration approved the expansion of the use of the oral MS therapy Gilenya® (fingolimod, Novartis AG) to include the treatment of children and adolescents 10 years of age or older with relapsing MS. In addition, many...

    https://mschristian.org/index.php/blog/treating-pediatric-ms
  • Studies Report on Efforts to Optimize Rituximab in MS, NMOSD - The Center for Biosimilars

    multiple sclerosis (MS) or aquaporin-4-positive (AQP4) neuromyelitis optica spectrum disorder (NMOSD), the CD20-depleting therapy and its biosimilars are commonly used off-label, as the therapy has been demonstrated to be effective in reducing relapses...

    https://mschristian.org/index.php/blog/studies-report-on-efforts-to-optimize-rituximab-in-ms-nmosd-the-center-for-biosimilars
  • Music Therapy for MS: How Rhythm Can Help With Movement and Memory

    you developed multiple sclerosis (MS)? Is your walking affected? One approach that may give you your rhythm back is music therapy — a type of therapy that uses music to address physical, emotional, cognitive, or social needs of individuals. How can...

    https://mschristian.org/index.php/blog/music-therapy-for-ms-how-rhythm-can-help-with-movement-and-memory
  • Sanofi and Happify Health solidify collaboration around prescription DTx designed to address mental health in people with MS

    quality of life.” The collaboration willcreate — and study via clinical trials — an app that introduces cognitive behavior therapy to help improve mental health through education and other activities. “Patients are getting more interested in their own...

    https://mschristian.org/index.php/blog/sanofi-and-happify-health-solidify-collaboration-around-prescription-dtx-designed-to-address-mental-health-in-people-with-ms
  • Handling Stress - Mind-Body Basics for People with MS

    therapies like mindfulness meditation to help manage their symptoms and reduce stress. How Exactly Can Mind-Body Therapy Help? The term “mind-body therapy” refers to a group of healing techniques that can induce relaxation and improve overall health and...

    https://mschristian.org/index.php/blog/handling-stress-mind-body-basics-for-people-with-ms
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    by end of 2019. If approved, ofatumumab will potentially become a treatment for a broad RMS population and the first B-cell therapy that can be self-administered at home Basel, August 30, 2019 – Novartis, a global leader in neuroscience, today announced...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies
  • Novel PET imaging agent could help guide therapy for brain diseases

    Cite This Page: Society of Nuclear Medicine and Molecular Imaging. "Novel PET imaging agent could help guide therapy for brain diseases." ScienceDaily. ScienceDaily, 2 April 2018. . Society of Nuclear Medicine and Molecular Imaging. (2018, April 2)....

    https://mschristian.org/index.php/blog/novel-pet-imaging-agent-could-help-guide-therapy-for-brain-diseases
  • UA receives $37.5 million NIH grant to research potential regenerative therapy for Alzheimer's

    Science has received a $37.5 million grant from the National Institutes of Health to research a potential regenerative therapy for Alzheimer's disease. A team led by Roberta Diaz Brinton, PhD, director of the Center for Innovation in Brain Science,...

    https://mschristian.org/index.php/blog/ua-receives-37-5-million-nih-grant-to-research-potential-regenerative-therapy-for-alzheimer-s
  • Northwestern University Stem Cell Therapy Clinic Closes Abruptly - The Scientist

    University Stem Cell Therapy Clinic Closes Abruptly The Scientist A pioneering stem cell clinical trial program in the US is closing up shop, a surprise move for what had appeared to be a successful endeavor at testing... Original link Northwestern...

    https://mschristian.org/index.php/blog/northwestern-university-stem-cell-therapy-clinic-closes-abruptly-the-scientist
  • Carisma Therapeutics Announces Investor Conference Participation - P&T Community

    of both the innate and adaptive immune responses. Carisma's proprietary chimeric antigen receptor (CAR)-macrophage cell therapy platform is designed to address key challenges involved in the treatment of solid tumors by actively trafficking to the...

    https://mschristian.org/index.php/blog/carisma-therapeutics-announces-investor-conference-participation-p-t-community
  • Prescription digital therapeutics: reimagining disease treatment - STAT

    reSET-O provides patients who are taking medication for opioid-use disorder with instantly accessible cognitive behavioral therapy, which is designed to help patients change for the better the ways they think and behave. Smartphones and tablets have...

    https://mschristian.org/index.php/blog/prescription-digital-therapeutics-reimagining-disease-treatment-stat
  • MS Patients Have Low Blood Levels of Infection-fighting Antibodies, Study Finds - Multiple Sclerosis News Today

    serum of certain antibodies that can protect against infection, regardless of whether they are using a disease-targeted therapy or not, a study reports. These levels were not so low as to risk infection on their own, but were lower-than-normal across...

    https://mschristian.org/index.php/blog/ms-patients-have-low-blood-levels-of-infection-fighting-antibodies-study-finds-multiple-sclerosis-news-today
  • Rethinking neurodegenerative disease treatment: Target multiple pathological proteins

    many aging patients. The prevalence of these co-pathologies suggests that each disease may ultimately require combination therapy targeting multiple disease proteins, and not just a single therapy, in patients with both early and later-stage disease....

    https://mschristian.org/index.php/blog/rethinking-neurodegenerative-disease-treatment-target-multiple-pathological-proteins
  • #ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

    versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS.“ What therapy to choose, and for how long to take it, have been emerging issues for women with MS who are pregnant or planning to become...

    https://mschristian.org/index.php/blog/ectrims2019-tysabri-during-pregnancy-and-after-delivery-seems-safe-reduces-relapse-risk-study-finds
  • A Cheap Biotech Stock Tests a Novel Treatment for Multiple Sclerosis - Barron's

    that’s in early clinical trials. At an international meeting of MS doctors on Friday, researchers reported that Atara’s therapy showed hints of actually improving the condition of MS patients, instead of just slowing the disease like most available...

    https://mschristian.org/index.php/blog/a-cheap-biotech-stock-tests-a-novel-treatment-for-multiple-sclerosis-barron-s
  • What to know about MS fatigue

    Treatment plans differ among individuals, but most involve a combination of some of the following: occupational therapy to learn how to save energy while doing daily tasks physical therapy to develop an exercise program that can prevent muscle wasting...

    https://mschristian.org/index.php/blog/what-to-know-about-ms-fatigue
  • Research on immune activity in MS

    phase of MS. We’re making progress Studies of the immune system in MS laid the groundwork for every disease-modifying therapy now available, and these studies continue to hold promise for finding ways to stop MS. Here are reports of recent progress:...

    https://mschristian.org/index.php/blog/research-on-immune-activity-in-ms

Results 1 - 20 of 66
 
 

Follow Us on Twitter

Follow Us On Twitter - Image